Mereo BioPharma Group (STU:MAH0) EBIT : €-40.74 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Mereo BioPharma Group EBIT?

Mereo BioPharma Group's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was €-13.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was €-40.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mereo BioPharma Group's annualized ROC % for the quarter that ended in Sep. 2024 was -367.64%. Mereo BioPharma Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -4,527.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mereo BioPharma Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -14.57%.

Mereo BioPharma Group EBIT Historical Data

The historical data trend for Mereo BioPharma Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group EBIT Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-42.84

-179.31

21.79

-36.59

-24.87

Mereo BioPharma Group Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-5.46	-8.52	-7.95	-11.08	-13.20

Competitive Comparison of Mereo BioPharma Group's EBIT

For the Biotechnology subindustry, Mereo BioPharma Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's EV-to-EBIT falls into.

Mereo BioPharma Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-40.74 Mil.

Mereo BioPharma Group (STU:MAH0) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mereo BioPharma Group's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-32.964 * ( 1 - 0% )	/	( (8.597	+	9.336)	/ 2 )
=	-32.964	/	8.9665
=	-367.64 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	89.304	-	7.805	-	( 81.223	-	max(0, 14.368	-	87.27	+	81.223	))
=	8.597

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	79.96	-	5.288	-	( 72.55	-	max(0, 12.801	-	78.137	+	72.55	))
=	9.336

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Mereo BioPharma Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-52.792	/	( ( (1.229 + max(-7.08, 0))	+	(1.103 + max(-4.111, 0)) )	/	2 )
=	-52.792	/	( ( 1.229	+	1.103 )	/	2 )
=	-52.792	/	1.166
=	-4,527.62 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.076)	-	(7.805	+	0.256	+	1.095)
=	-7.08

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.025)	-	(5.288	+	0.258	+	1.59)
=	-4.111

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mereo BioPharma Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-40.742	/	279.646
	=	-14.57 %

Mereo BioPharma Group EBIT Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (STU:MAH0) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

MREO:USA 0A9G:UK

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines